Huiyu Pharmaceutical: Three products are expected to win bids in the twelfth national centralized drug procurement.

Huiyu Pharmaceutical announced that the company is participating in the twelfth batch of national centralized drug procurement bidding, with three products expected to win bids: injectable hydrochloride bijuxtine, injectable teicoplanin, and calcium levofolinate injection. The procurement period will last until December 31, 2029. Before winning the bid, these three products had generated sales revenue of 35.1844 million yuan, 1.3324 million yuan, and 246,400 yuan, respectively. If procurement contracts are signed and implemented subsequently, it will expand product sales and enhance performance. However, due to the regularization of centralized procurement, there is uncertainty regarding subsequent matters and performance impact.